Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.255 -2.695 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.29 Bil PE Ratio: 0 PB Ratio: 1,065.02 GF Score: 78/100

Alnylam Pharmaceuticals Inc at Chardan Genetic Medicines Conference (Virtual) Transcript

Oct 05, 2020 / 08:15PM GMT
Release Date Price: $142 (+4.66%)
Keay Thomas Nakae
Chardan Capital Markets, LLC, Research Division - Senior Research Analyst of Therapeutics, Devices and Diagnostics

Good afternoon, and welcome to this special topic discussion RNA interference, strategies for success outside the liver. My name is Keay Nakae, and I'm one of the senior health care analysts here at Chardan. Joining me for this discussion is Dr. Pushkal Garg, Chief Medical Officer at Alnylam Pharmaceuticals.

Dr. Garg is an influential thought leader in the area of siRNA therapeutics. Dr. Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. At Alnylam, he oversees all clinical development activities. He also serves on the Board of Directors at SQZ Biotechnologies.

Pushkal, welcome, and thank you for being with us today.

Pushkal Garg
Alnylam Pharmaceuticals, Inc. - Chief Medical Officer

Thanks, Keay. Delighted to be here. Thanks for inviting me.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot